Defining metabolic activity of nephrolithiasis - Appropriate evaluation and follow-up of stone formers

doi:10.1016/j.ajur.2018.06.007

Asian Journal of Urology, 2018, 5 (4): 235-242 doi: 10.1016/j.ajur.2018.06.007

Reviews

Current Issue | Archive | Adv Search

Defining metabolic activity of nephrolithiasis - Appropriate evaluation and follow-up of stone formers

Daniel A. Wollin^a^*(

),Adam G. Kaplan^a,Glenn M. Preminger^a,Pietro Manuel Ferraro^b,Antonio Nouvenne^c,Andrea Tasca^d,Emanuele Croppi^b,Giovanni Gambaro^b,Ita P. Heilberg^e

^a. Duke Comprehensive Kidney Stone Center, Division of Urologic Surgery, Duke University Medical Center, Durham, NC, USA
^b. Columbus-Gemelli University Hospital, Division of Nephrology, Department of Medical Sciences, Rome, Italy
^c. University of Parma, Department of Clinical and Experimental Medicine, Parma, Italy
^d. S. Bortolo Hospital, Department of Urology, Vicenza, Italy
^e. Universidade Federal de Sã Paulo, Nephrology Division, Sã Paulo, Brazil

Abstract
Related Citation (13)

Download:

HTML

PDF (880KB)
Export: BibTeX | EndNote (RIS)

Abstract

Considering the variation in metabolic evaluation and medical management of kidney stone disease, this consensus review was created to discuss the metabolic activity of nephrolithiasis, define the difference between single and recurrent stone formers, and develop a schema for metabolic and radiologic follow-up. A systematic review of the literature was performed to identify studies of metabolic evaluation and follow-up of patients with nephrolithiasis. Both single and recurrent stone formers share many similarities in metabolic profiles. The study group determined that based on an assessment of risk for stone recurrence and metabolic activity, single and recurrent stone formers should be evaluated comprehensively, including two 24 h urine studies on a random diet. Targeted medication and dietary recommendations are effective for many patients in reducing the risk of stone recurrence. Follow-up of those with stone disease should be obtained depending on the level of metabolic activity of the patient, the risk of chronic kidney diseaseand the risk of osteoporosis/osteopenia. A standard scheme includes a baseline metabolic profile, a repeat study 3-6 months after initiation of treatment, and then yearly when stable, with abdominal imaging obtained every 1-2 years.

Key words： Follow-up Medical management Metabolic evaluation Urolithiasis

Received: 09 November 2017 Published: 19 November 2018

Corresponding Authors: A. Wollin Daniel E-mail: daniel.wollin@duke.edu

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	A. Wollin Daniel
	G. Kaplan Adam
	M. Preminger Glenn
	Manuel Ferraro Pietro
	Nouvenne Antonio
	Tasca Andrea
	Croppi Emanuele
	Gambaro Giovanni
	P. Heilberg Ita

TRENDMD:

Cite this article:

A. Wollin Daniel,G. Kaplan Adam,M. Preminger Glenn, et al. Defining metabolic activity of nephrolithiasis - Appropriate evaluation and follow-up of stone formers[J]. Asian Journal of Urology, 2018, 5(4): 235-242.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2018.06.007 OR http://www.ajurology.com/EN/Y2018/V5/I4/235

[1]	Chandhoke PS . Evaluation of the recurrent stone former. UrolClin N Am 2007; 34:315e22.
[2]	Strauss AL, Coe FL, Parks JH . Formation of a single calciumstone of renal origin: clinical and laboratory characteristics ofpatients. Arch Intern Med 1982; 142:504e7. doi: 10.1001/archinte.1982.00340160084019 pmid: 7065787
[3]	Pak C . Should patients with single renal stone occurrenceundergo diagnostic evaluation? J Urol 1982; 127:855e8. pmid: 7086982
[4]	Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM . Abnormalitiesof 24-h urine composition in first-time and recurrentstone-formers. Urology 2012; 80:776e9. doi: 10.1016/j.urology.2012.06.034 pmid: 22921696
[5]	Strauss AL, Coe FL, Deutsch L, Parks JH . Factors that predictrelapse of calcium nephrolithiasis during treatment. Am J Med1982; 72:17e25.
[6]	Gambaro G, Reis-Santos JM, Rao N . Nephrolithiasis: whydoesn’t our “Learning” progress? Eur Urol 2004; 45:547e56.
[7]	Rule AD, Lieske JC, Li X, Melton LJ, Krambeck AE, Bergstralh EJ . The ROKS nomogram for predicting a secondsymptomatic stone episode. J Am Soc Nephrol 2014; 1:2878e86. doi: 10.1681/ASN.2013091011 pmid: 25104803
[8]	Qaseem A, Dallas P, Forciea MA, Starkey M, Denberg TD . Dietaryand pharmacologic management to prevent recurrentnephrolithiasis in adults: a clinical practice guideline from theAmerican college of physicians. Ann Intern Med 2014; 161:659e67. doi: 10.7326/M13-2908 pmid: 25364887
[9]	Mardis HK, Parks JH, Muller G, Ganzel K, Coe FL . Outcome ofmetabolic evaluation and medical treatment for calciumnephrolithiasis in a private urological practice. J Urol 2004; 171:85e8. doi: 10.1097/01.ju.0000099789.99127.6b pmid: 14665850
[10]	Lingeman J, Mardis H, Kahnoski R, Goldfarb DS, Lacy S, Grasso M , et al. Medical reduction of stone risk in a network oftreatment centers compared to a research clinic. J Urol 1998; 160:1629e34.
[11]	Fink HA, Wilt TJ, Eidman KE, Garimella PS , MacDonald R,Rutks IR, et al.Recurrent nephrolithiasis in adults: comparativeeffectiveness of preventive medical strategies [Internet].Rockville (MD): Agency for Healthcare Research and Quality(US); 2012 [cited 2015 Mar 1]. (AHRQ Comparative EffectivenessReviews). Available from: .
[12]	Goldfarb DS, Arowojolu O . Metabolic evaluation of first-timeand recurrent stone formers. Urol Clin N Am 2013; 40:13e20. doi: 10.1016/j.ucl.2012.09.007 pmid: 4052537
[13]	Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR , et al. Medical management of kidneystones: AUA guideline. J Urol 2014; 192:316e24. doi: 10.1016/j.juro.2014.05.006 pmid: 24857648
[14]	Parks JH, Coe FL, Evan AP, Worcester EM . Clinical and laboratorycharacteristics of calcium stone-formers with and withoutprimary hyperparathyroidism. BJU Int 2009; 103:670e8. doi: 10.1111/j.1464-410X.2008.08064.x pmid: 18793297
[15]	Kourambas J, Aslan P, Teh CL, Mathias BJ, Preminger GM . Roleof stone analysis in metabolic evaluation and medical treatmentof nephrolithiasis. J Endourol 2001; 15:181e6. doi: 10.1089/089277901750134548 pmid: 11325090
[16]	Milose JC, Kaufman SR, Hollenbeck BK, Wolf JS, Hollingsworth JM . Prevalence of 24-hour urine collection inhigh risk stone formers. J Urol 2014; 191:376e80. doi: 10.1016/j.juro.2013.08.080 pmid: 24018242
[17]	Bensalah K, Tuncel A, Raman JD, Bagrodia A, Pearle M, Lotan Y . How physician and patient perceptions differregarding medical management of stone disease. J Urol 2009; 182:998e1004. doi: 10.1016/j.juro.2009.05.025 pmid: 19616801
[18]	Chandhoke PS . When is medical prophylaxis cost-effective forrecurrent calcium stones? J Urol 2002; 168:937e40. doi: 10.1016/S0022-5347(05)64546-6 pmid: 12187194
[19]	Tasca A, Dalle Carbonare L, Nigro F, Giannini S . Bone diseasein patients with primary hypercalciuria and calcium nephrolithiasis. Urology 2009; 74:22e7. doi: 10.1016/j.urology.2008.11.014 pmid: 19428073
[20]	Gomes SA, dos Reis LM, Noronha IL, Jorgetti V, Heilberg IP . RANKL is a mediator of bone resorption in idiopathic hypercalciuria. Clin J Am Soc Nephrol CJASN 2008; 3:1446e52. doi: 10.2215/CJN.00240108 pmid: 18480302
[21]	Menon VB, Moysés RMA , Gomes SA, de Carvalho AB, Jorgetti V,Heilberg IP. Expression of fibroblast growth factor 23, vitaminD receptor, and sclerostin in bone tissue from hypercalciuricstone formers. Clin J Am Soc Nephrol CJASN 2014; 9:1263e70. doi: 10.2215/CJN.10030913 pmid: 24763863
[22]	Lauderdale DS, Thisted RA, Wen M, Favus MJ . Bone mineraldensity and fracture among prevalent kidney stone cases inthe third national health and nutrition examination survey. JBone Miner Res 2001; 16:1893e8. doi: 10.1359/jbmr.2001.16.10.1893 pmid: 11585355
[23]	Melton LJ, Crowson CS, Khosla S, Wilson DM , O’Fallon WM.Fracture risk among patients with urolithiasis: a populationbasedcohort study. Kidney Int 1998; 53:459e64. doi: 10.1046/j.1523-1755.1998.00779.x pmid: 9461107
[24]	Fine JK, Pak CY, Preminger GM . Effect of medical managementand residual fragments on recurrent stone formationfollowing shock wave lithotripsy. J Urol 1995; 153:27e33. doi: 10.1007/978-1-4615-2556-1_194 pmid: 7966783
[25]	Kang DE, Maloney MM, Haleblian GE, Springhart WP, Honeycutt EF, Eisenstein EL , et al. Effect of medical managementon recurrent stone formation following percutaneousnephrolithotomy. J Urol 2007; 177:1785e9. doi: 10.1016/j.juro.2007.01.061 pmid: 17437820
[26]	Kocvara R, Plasgura P , Pet?ík A, Louzensky G, Bartoní?kováK,Dvorácek J. A prospective study of nonmedical prophylaxisafter a first kidney stone. BJU Int 1999; 84:393e8. doi: 10.1046/j.1464-410x.1999.00216.x pmid: 10468751
[27]	Castle SM, Cooperberg MR, Sadetsky N, Eisner BH, Stoller ML . Adequacy of a single 24-hour urine collection for metabolicevaluation of recurrent nephrolithiasis. J Urol 2010; 184:579e83. doi: 10.1016/j.juro.2010.03.129 pmid: 20639021
[28]	Pak CY, Peterson R, Poindexter JR . Adequacy of a single stonerisk analysis in the medical evaluation of urolithiasis. J Urol2001; 165:378e81. doi: 10.1097/00005392-200102000-00006 pmid: 11176377
[29]	Healy KA, Hubosky SG, Bagley DH . 24-Hour urine collection inthe metabolic evaluation of stone formers: is one studyadequate? J Endourol 2013; 27:374e8. doi: 10.1089/end.2012.0216 pmid: 22967013
[30]	Nayan M, Elkoushy MA , Andonian S. Variations between two24-hour urine collections in patients presenting to a tertiarystone clinic. Can Urol Assoc J 2012; 6:30. 11131.
[31]	Parks JH, Goldfisher E, Asplin JR, Coe FL . A single 24-hoururine collection is inadequate for the medical evaluation ofnephrolithiasis. J Urol 2002; 167:1607e12. doi: 10.1016/S0022-5347(05)65163-4 pmid: 11912373
[32]	Sawyer MD, Anderson CB, Viprakasit DP, Dietrich MS, Herrell SD, Miller NL . An individualized weight-based goalurine volume model significantly improves expected calciumconcentrations relative to a 2-L goal urine volume. Urolithiasis2013; 41:403e9. doi: 10.1007/s00240-013-0573-8 pmid: 23857331
[33]	Borghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A . Urinary volume, water and recurrences in idiopathic calciumnephrolithiasis: a 5-year randomized prospective study. J Urol1996; 155:839e43.
[34]	Heilberg IP, Goldfarb DS . Optimum nutrition for kidney stonedisease. Adv Chronic Kidney Dis 2013; 20:165e74.
[35]	Taylor EN, Curhan GC . Dietary calcium from dairy andnondairy sources, and risk of symptomatic kidney stones. JUrol 2013; 190:1255e9. doi: 10.1016/j.juro.2013.03.074 pmid: 23535174
[36]	Curhan GC, Willett WC, Rimm EB, Stampfer MJ . A prospectivestudy of dietary calcium and other nutrients and the risk ofsymptomatic kidney stones. N Engl J Med 1993; 328:833e8.
[37]	Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U , et al. Comparison of two diets for the prevention of recurrentstones in idiopathic hypercalciuria.NEngl JMed2002; 346:77e84.
[38]	Pak CYC, Heller HJ, Pearle MS, Odvina CV, Poindexter JR, Peterson RD . Prevention of stone formation and bone Loss inabsorptive hypercalciuria by combined dietary and pharmacologicalinterventions. J Urol 2003; 169:465e9. doi: 10.1016/S0022-5347(05)63934-1 pmid: 12544288
[39]	Robinson MR, Leitao VA, Haleblian GE, Scales Jr CD, Chandrashekar A, Pierre SA , et al. Impact of long-term potassiumcitrate therapy on urinary profiles and recurrent stoneformation. J Urol 2009; 181:1145e50. doi: 10.1016/j.juro.2008.11.014 pmid: 19152932
[40]	Eisner BH, Goldfarb DS . A nomogram for the prediction ofkidney stone recurrence. J Am Soc Nephrol 2014; 25:2685e7. doi: 10.1681/ASN.2014060631 pmid: 25104802
[41]	Huen SC, Goldfarb DS . Adverse metabolic side effects of thiazides:implications for patients with calcium nephrolithiasis. J Urol 2007; 177:1238e43. doi: 10.1016/j.juro.2006.11.040 pmid: 17382697
[42]	Fulgham PF, Assimos DG, Pearle MS, Preminger GM . Clinicaleffectiveness protocols for imaging in the management ofureteral calculous disease: AUA technology assessment. J Urol2013; 189:1203e13. doi: 10.1016/j.juro.2012.10.031 pmid: 23085059
[43]	Mermuys K, De Geeter F, Bacher K , Van De Moortele K,Coenegrachts K, Steyaert L, et al. Digital tomosynthesis in thedetection of urolithiasis: diagnostic performance and dosimetrycompared with digital radiography with MDCT as thereference standard. AJR Am J Roentgenol 2010; 195:161e7. doi: 10.2214/AJR.09.3075 pmid: 20566811
[44]	Cabrera FJ, Kaplan AG, Youssef RF, Tsivian M, Shin RH, Scales CD , et al. Digital tomosynthesis: a viable alternative tononcontrast computed tomography for the follow-up ofnephrolithiasis? J Endourol 2016; 30:366e70. doi: 10.1016/j.juro.2016.02.1982 pmid: 27078715
[45]	Bansal AD, Hui J, Goldfarb DS . Asymptomatic nephrolithiasisdetected by ultrasound. Clin J Am Soc Nephrol 2009; 4:680e4. doi: 10.2215/CJN.05181008 pmid: 19261817
[46]	Kang HW, Lee SK, Kim WT, Kim YJ, Yun SJ, Lee SC , et al. Natural history of asymptomatic renal stones and predictionof stone related events. J Urol 2013; 189:1740e6. doi: 10.1016/j.juro.2012.11.113 pmid: 23201376
[47]	Burgher A, Beman M, Holtzman JL, Monga M . Progression ofnephrolithiasis: long-term outcomes with observation ofasymptomatic calculi. J Endourol 2004; 18:534e9. doi: 10.1089/end.2004.18.534 pmid: 15333216
[48]	Rosenbaum L . Beyond beliefdhow people feel about takingmedications for heart disease. N Engl J Med 2015; 372:183e7. doi: 10.1056/NEJMms1409015 pmid: 25564902
[49]	Parks JH, Coe FL . Evidence for durable kidney stone preventionover several decades. BJU Int 2009; 103:1238e46. doi: 10.1111/j.1464-410X.2008.08170.x pmid: 2768493